Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 246

1.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A.

Nature. 2005 Apr 14;434(7035):917-21.

2.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T.

Nature. 2005 Apr 14;434(7035):913-7. Erratum in: Nature. 2007 May 17;447(7142):346.

3.

Therapeutic exploitation of tumor cell defects in homologous recombination.

Powell SN, Kachnic LA.

Anticancer Agents Med Chem. 2008 May;8(4):448-60. Review.

PMID:
18473729
4.

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ.

J Natl Cancer Inst. 2011 Feb 16;103(4):334-46. doi: 10.1093/jnci/djq509. Epub 2010 Dec 23.

PMID:
21183737
5.

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A.

Cancer Res. 2006 Aug 15;66(16):8109-15.

6.

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.

McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A.

Cancer Biol Ther. 2005 Sep;4(9):934-6. Epub 2005 Sep 1.

PMID:
16251802
7.

Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy.

Hay T, Jenkins H, Sansom OJ, Martin NM, Smith GC, Clarke AR.

Cancer Res. 2005 Nov 15;65(22):10145-8. Erratum in: Cancer Res. 2006 Jan 1;66(1):599.

8.

Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.

Yap TA, Sandhu SK, Carden CP, de Bono JS.

CA Cancer J Clin. 2011 Jan-Feb;61(1):31-49. doi: 10.3322/caac.20095. Epub 2011 Jan 4. Review.

9.

Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy.

Plummer ER, Calvert H.

Clin Cancer Res. 2007 Nov 1;13(21):6252-6. Review.

10.

Development of PARP inhibitors in oncology.

Rodon J, Iniesta MD, Papadopoulos K.

Expert Opin Investig Drugs. 2009 Jan;18(1):31-43. doi: 10.1517/13543780802525324 . Review.

PMID:
19053880
11.

BRCA in breast cancer: from risk assessment to therapeutic prediction.

Diamond JR, Borges VF, Eckhardt SG, Jimeno A.

Drug News Perspect. 2009 Dec;22(10):603-8. doi: 10.1358/dnp.2009.22.10.1440985. Review.

PMID:
20140280
12.

Base excision repair is efficient in cells lacking poly(ADP-ribose) polymerase 1.

Vodenicharov MD, Sallmann FR, Satoh MS, Poirier GG.

Nucleic Acids Res. 2000 Oct 15;28(20):3887-96.

13.

[PARP inhibitors for cancer therapy].

Saito H, Miki Y.

Gan To Kagaku Ryoho. 2011 Jan;38(1):12-8. Japanese.

PMID:
21368455
14.

The potential of PARP inhibitors in genetic breast and ovarian cancers.

Drew Y, Calvert H.

Ann N Y Acad Sci. 2008 Sep;1138:136-45. doi: 10.1196/annals.1414.020.

PMID:
18837894
15.

Involvement of poly(ADP-ribose) polymerase in base excision repair.

Dantzer F, Schreiber V, Niedergang C, Trucco C, Flatter E, De La Rubia G, Oliver J, Rolli V, Ménissier-de Murcia J, de Murcia G.

Biochimie. 1999 Jan-Feb;81(1-2):69-75. Review.

PMID:
10214912
16.

Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?

Shall S, de Murcia G.

Mutat Res. 2000 Jun 30;460(1):1-15. Review.

PMID:
10856830
17.
18.
19.

Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.

Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, Jackson SP, Smith GC, Ashworth A.

Cold Spring Harb Symp Quant Biol. 2005;70:139-48.

PMID:
16869747
20.

Supplemental Content

Support Center